ALLO 1.87 (+1.63%)
US0197701065BiotechnologyBiotechnology

Allogene Therapeutics (ALLO) Stock Highlights

1.87 | +1.63%
2024-12-21 05:07:55
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Statistics

Range Today
1.78 1.93
Volume Today 4.99M
Range 1 Year
1.78 5.78
Volume 1 Year 624.56M
Range 3 Year
1.78 17.49
Volume 3 Year 1.63B
Range 10 Year
1.78 55
Volume 10 Year 2.31B

Highlights

Market Capitalization 645.79M (small)
Floating Shares 151.72M
Current Price 1.87
Price To Earnings -2.09
Price To Revenue 19.97K
Price To Book 1.39
Earnings Per Share -1.55
Payout Ratio 0%

Performance

Latest +1.63%
1 Month -11.37%
3 Months -34.62%
6 Months -17.26%
1 Year -36.61%
3 Years -87.94%
5 Years -93.07%
10 Years -91.5%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.